Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;13(4):845-850.
doi: 10.5114/aoms.2016.58647. Epub 2016 Mar 17.

Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?

Ewelina Lukaszyk  1 , Mateusz Lukaszyk  2 , Ewa Koc-Zorawska  1 , Anna Bodzenta-Lukaszyk  2 , Jolanta Malyszko  1
Affiliations

Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?

Ewelina Lukaszyk et al. Arch Med Sci. 2017 Jun.

Abstract

Introduction: Fibroblast growth factor 23 (FGF-23) levels are elevated in impaired renal function. Inflammation and iron are potential regulators of FGF-23. The aim of the study was to evaluate the association between FGF-23 concentration, novel iron status biomarkers and inflammatory parameters among patients with early stages of chronic kidney disease (CKD).

Material and methods: The study population included 84 patients with CKD in the early stage. Serum hemoglobin, fibrinogen, creatinine, iron, transferrin saturation and ferritin levels were measured using standard laboratory methods. Commercially available kits were used to measure: intact FGF-23, hepcidin, soluble transferrin receptor (sTfR), interleukin 6 (IL-6) and high-sensitivity C-reactive protein (hsCRP).

Results: In patients with CKD no differences in FGF-23 concentration according to iron status were observed. Lower iron concentration was associated with higher concentrations of hsCRP, IL-6 and fibrinogen. In univariate and multivariate analysis FGF-23 correlated with fibrinogen (r = -0.23, p < 0.05) and eGFR (r = -0.36, p < 0.05).

Conclusions: FGF-23 is affected by kidney function and fibrinogen but not iron status parameters in the early stages of CKD. Our data are paving the way for further studies on the role of FGF-23 in iron metabolism, especially in early stages of CKD.

Keywords: chronic kidney disease; fibroblast growth factor 23; inflammation; iron.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation between iFGF-23 and fibrinogen in patients with CKD, stage 2 (r = −0.4, p < 0.05)
See this image and copyright information in PMC

References

    1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–53. - PMC - PubMed
    1. Rysz J, Gluba-BrzÓzka A, Mikhailidis DP, Banach M. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015;24:603–10. - PubMed
    1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–8. - PubMed
    1. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427–35. - PubMed
    1. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant. 2009;24:4–7. - PMC - PubMed